The implementation of CAR T-cell therapy as a standard of care in British Columbia marks a significant advancement in cancer treatment accessibility for both pediatric and adult patients. Internationally, the approval of the world's first CRISPR-Cas9 genome editing therapies for sickle cell disease in the UK and US represents a major milestone in the field of gene therapy. In this session, we will explore how gene and immune engineering is transforming precision medicine, offering new hope for patients with rare genetic conditions and cancer. Join us to discover how these innovative approaches are paving the way for breakthroughs in medical science.